The effect of oral melatonin on the quality of life, sleep and blood pressure of renal failure patients

Phase 3

Recruiting

Conditions: Chronic kidney disease.
Chronic kidney disease (CKD)

Registration Number: IRCT20230205057333N1

Lead Sponsor: Yasouj University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 82

Inclusion Criteria

Age above 18 years
Ability to give informed consent
The duration of hemodialysis is at least 3 months

Exclusion Criteria

Peritoneal Dialysis
Known major disease (malignancy, uncontrolled infection, uncontrolled heart failure)
pregnancy
Acute medical or surgical illness that requires hospitalization or surgery
severe psychological illness (severe depression, psychosis, dementia)
History of sensitivity to melatonin

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sleep quality. Timepoint: At the beginning of the study and at the end of the sixth week. Method of measurement: Pittsburgh Sleep Quality Questionnaire (PSQI).;Quality of Life. Timepoint: At the beginning of the study and at the end of the sixth week. Method of measurement: Quality of Life Questionnaire of Kidney Patients (KDQOL - SF™ 1/3).;Blood pressure. Timepoint: At the beginning of study, at the end of the third and sixth week. Method of measurement: In all patients, systolic and diastolic blood pressure during dialysis will be measured and recorded using erka sphygmomanometer.

Secondary Outcome Measures